Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2018 /
Muscle density as a predictive marker for toxicities during ovarian cancer treatment

16th - 18th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.11.18
Views: 615

Dr Lucy Dumas - The Royal Marsden NHS Foundation Trust, London, UK

Dr Lucy Dumas speaks to ecancer at the International Society of Geriatric Oncology 2018 conference in Amsterdam about toxicities for women with ovarian cancer.

She used muscle density a a predictive marker and found that women with lower muscle density at the start of treatment had shorter overall survival.

Dr Dumas emphasises the importance of the importance of understanding the whole patient rather than just the cancer, for example by incorporating a geriatric assessment.

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation